{"denoms":[{"counts":[{"groupId":"BG000","value":"789"},{"groupId":"BG001","value":"833"},{"groupId":"BG002","value":"409"},{"groupId":"BG003","value":"2031"}],"units":"Participants"}],"groups":[{"description":"Nivolumab + Xelox: Nivolumab 360 mg IV over 30 minutes on Day 1 of each treatment cycle, every 3 weeks + Oxaliplatin 130 mg/m2 IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m2 orally twice daily (ie, 1000 mg/m2 in the morning and 1000 mg/m2 in the evening) on Days 1 to 14 of each treatment cycle, every 3 weeks\n\nNivolumab + Folfox: Nivolumab 240 mg IV over 30 minutes on Day 1 of each treatment cycle, every 2 weeks + Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours (or per local standard) daily on Days 1 and 2 of each treatment cycle, every 2 weeks","id":"BG000","title":"Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)"},{"description":"Chemotherapy (XELOX or FOLFOX): Xelox: Oxaliplatin 130 mg/m2 IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m2 orally twice daily (ie, 1000 mg/m2 in the morning and 1000 mg/m2 in the evening) on Days 1 to 14 of each treatment cycle, every 3 weeks. Folfox: Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours (or per local standard) daily on Days 1 and 2 of each treatment cycle, every 2 weeks. This chemotherapy group consists of the two comparison chemotherapy sub-groups. Arm 2a (792 participants) is the comparison group to Arm 1 and Arm 2b (404 participants) is the comparison group to Arm 3. Some participants were counted in both Arm 2a and Arm 2b.","id":"BG001","title":"Arm 2: Chemotherapy (XELOX or FOLFOX)"},{"description":"1 mg/kg nivolumab administered IV over 30 minutes followed by ipilimumab 3 mg/kg administered IV over 30 minutes on Day 1 of each treatment cycle every 3 weeks for 4 doses (Cycles 1 to 4), followed by nivolumab 240 mg administered IV over 30 minutes on Day 1 of each treatment cycle every 2 weeks (Cycle 5 and beyond). Arm is closed to enrollment as of 05-June-2018.","id":"BG002","title":"Arm 3: Nivolumab + Ipilimumab"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.9","value":"60.3"},{"groupId":"BG001","spread":"12.1","value":"59.8"},{"groupId":"BG002","spread":"11.7","value":"59.4"},{"groupId":"BG003","spread":"12.0","value":"59.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"246"},{"groupId":"BG002","value":"131"},{"groupId":"BG003","value":"626"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"540"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"278"},{"groupId":"BG003","value":"1405"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"26"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"124"},{"groupId":"BG003","value":"510"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"24"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"556"},{"groupId":"BG001","value":"570"},{"groupId":"BG002","value":"264"},{"groupId":"BG003","value":"1390"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"81"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}